Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Helmick CG, Lee-Han H, Hirsch SC, et al. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. Am J Prev Med. 2014;47(1):37–45.
   PubMed Web of Science ®Google Scholar
• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658.
   PubMed Web of Science ®Google Scholar
• Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961967e965.
   Web of Science ®Google Scholar
• Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65ii68; discussion ii69ii73.
   PubMedGoogle Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–284.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35(2 Pt 1):268–269.
   PubMed Web of Science ®Google Scholar
• Traulsen J. Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int J Dermatol. 2004;43(8):611–617.
   PubMed Web of Science ®Google Scholar
• Milde P, Hauser U, Simon T, et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol. 1991;97(2):230–239.
   PubMed Web of Science ®Google Scholar
• Jensen T, Sorensen S, Solvsten H, et al. The vitamin D3 receptor and retinoid X receptors in psoriatic skin: the receptor levels correlate with the receptor binding to DNA. Br J Dermatol. 1998;138(2):225–228.
   PubMed Web of Science ®Google Scholar
• Reichrath J, Munssinger T, Kerber A, et al. In situ detection of retinoid-X receptor expression in normal and psoriatic human skin. Br J Dermatol. 1995;133(2):168–175.
   PubMed Web of Science ®Google Scholar
• Tang J, Zhou R, Luger D, et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol. 2009;182(8):4624–4632.
   PubMed Web of Science ®Google Scholar
• Chen ML, Perez A, Sanan DK, et al. Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol. 1996;106(4):637–641.
   PubMed Web of Science ®Google Scholar
• Reichrath J, Perez A, Muller SM, et al. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol. 1997;77(4):268–272.
   PubMed Web of Science ®Google Scholar
• Tremezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: where are we standing and where will we be going? Dermatoendocrinol. 2011;3(3):180–186.
   PubMedGoogle Scholar
• Kragballe K, Iversen L. Calcipotriol. A new topical antipsoriatic. Dermatol Clin. 1993;11(1):137–141.
   PubMed Web of Science ®Google Scholar
• Dyring-Andersen B, Bonefeld CM, Bzorek M, et al. The vitamin D analogue calcipotriol reduces the frequency of CD8+ IL-17+ T cells in psoriasis lesions. Scand J Immunol. 2015;82(1):84–91.
   PubMed Web of Science ®Google Scholar
• Dovonex cream [package insert]. Parsippany (NJ): LEO Pharma; 2009.
   Google Scholar
• Calcipotriene solution [package insert]. Philadelphia (PA): Global Pharmaceuticals; 2012.
   Google Scholar
• Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018.
   PubMed Web of Science ®Google Scholar
• Souza A, Strober BE. Principles of topical therapy. In: Goldsmith LA, Katz SI, Gilchrest BA, et al., editors. Fitzpatrick’s dermatology in general medicine. New York (NY): McGraw-Hill; 2012.
   Google Scholar
• Taclonex ointment [package insert]. Parsippany (NJ): LEO Pharma; 2010.
   Google Scholar
• Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82(2):131–135.
   PubMed Web of Science ®Google Scholar
• Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147(2):316–323.
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205(4):389–393.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150(6):1167–1173.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004;209(4):308–313.
   PubMed Web of Science ®Google Scholar
• Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48(1):48–54.
   PubMed Web of Science ®Google Scholar
• Taclonex topical suspension [package insert]. Parsippany (NJ): LEO Pharma; 2014.
   Google Scholar
• Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20(4):465–471.
   PubMed Web of Science ®Google Scholar
• Menter A, Gold LS, Bukhalo M, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013;12(1):92–98.
   PubMed Web of Science ®Google Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study. J Eur Acad Dermatol Venereol. 2014;28(12):1723–1731.
   PubMed Web of Science ®Google Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol. 2015;29(12):2349–2355.
   PubMed Web of Science ®Google Scholar
• Enstilar foam [package insert]. Parsippany (NJ): LEO Pharma; 2015.
   Google Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468–1477.
   PubMed Web of Science ®Google Scholar
• Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - a randomized phase II study. J Dermatolog Treat. 2016;27(2):120–127.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Van De Kerkhof P. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp. J Eur Acad Dermatol Venereol. 2014;28(Suppl 2):10–21.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154(6):1155–1160.
   PubMed Web of Science ®Google Scholar
• Silver S, Tuppal R, Gupta AK, et al. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial. J Drugs Dermatol. 2013;12(8):882–887.
   PubMed Web of Science ®Google Scholar
• Taraska V, Tuppal R, Olesen M, et al. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg. 2016;20(1):44–51.
   PubMed Web of Science ®Google Scholar
• Norsgaard H, Kurdykowski S, Descargues P, et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–729.
   PubMed Web of Science ®Google Scholar
• Papp K, Berth-Jones J, Kragballe K, et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21(9):1151–1160.
   PubMed Web of Science ®Google Scholar
• Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology. 2008;217(2):107–113.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59(3):455–463.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009;160(1):170–176.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol. 2009;161(1):159–166.
   PubMed Web of Science ®Google Scholar
• Tyring S, Mendoza N, Appell M, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol. 2010;49(11):1328–1333.
   PubMed Web of Science ®Google Scholar
• Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008;217(4):321–328.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Debarre JM, Keddy-Grant J, et al. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age. Br J Dermatol. 2014;171(6):1470–1477.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Ganslandt C, Kurvits M, et al. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years. Pediatr Dermatol. 2015;32(1):28–35.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Levi E, Pathak P, et al. Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs. J Med Econ. 2013;16(12):1405–1413.
   PubMedGoogle Scholar
• Menter A, Abramovits W, Colon LE, et al. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol. 2009;8(1):52–57.
   PubMed Web of Science ®Google Scholar
• Rasmussen G, Bech LL, Nielsen TW. An applicator delivery system for fixed-combination calcipotriene plus betamethasone dipropionate topical suspension (Gel): innovating psoriasis vulgaris treatment through patient collaboration. Dermatol Ther (Heidelb). 2015;5(4):235–246.
   PubMedGoogle Scholar
• McCormack PL. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. Drugs. 2011;71(6):709–730.
   PubMed Web of Science ®Google Scholar
• Guenther LC. Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol). Skin Therapy Lett. 2009;14(4):1–4.
   PubMedGoogle Scholar
• Osier E, Gomez B, Eichenfield LF. Adolescent scalp psoriasis: update on topical combination therapy. J Clin Aesthet Dermatol. 2015;8(7):43–47.
   PubMedGoogle Scholar